Workflow
YISHENG PHARM(002566)
icon
Search documents
中药板块9月25日跌0.36%,恩威医药领跌,主力资金净流出4.62亿元
Market Overview - The Chinese medicine sector experienced a decline of 0.36% on September 25, with Enwei Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3853.3, down 0.01%, while the Shenzhen Component Index closed at 13445.9, up 0.67% [1] Stock Performance - Notable gainers included: - Weikang Pharmaceutical, closing at 25.25 with a rise of 9.83% and a trading volume of 135,600 shares, totaling 329 million yuan [1] - Yisheng Pharmaceutical, closing at 7.98 with a rise of 1.53% and a trading volume of 80,000 shares, totaling 6.41 million yuan [1] - Major decliners included: - Enwei Pharmaceutical, closing at 32.25 with a drop of 3.09% and a trading volume of 8,950 shares, totaling 2.91 million yuan [2] - Zhendong Pharmaceutical, closing at 6.85 with a drop of 2.97% and a trading volume of 508,400 shares [2] Capital Flow - The Chinese medicine sector saw a net outflow of 462 million yuan from institutional investors, while retail investors contributed a net inflow of 315 million yuan [2] - The table of capital flow indicates that: - Wanbangde had a net inflow of 23.44 million yuan from institutional investors, but a net outflow of 29.29 million yuan from retail investors [3] - Jilin Aodong experienced a net inflow of 21.10 million yuan from institutional investors, with outflows from both retail and speculative investors [3]
益盛药业:截至2025年9月19日公司股东总户数为19709户
Zheng Quan Ri Bao Wang· 2025-09-22 09:48
证券日报网讯益盛药业(002566)9月22日在互动平台回答投资者提问时表示,截至2025年9月19日,公 司股东总户数为19,709户。 ...
益盛药业:截至2025年9月10日,公司股东总户数20399户
Zheng Quan Ri Bao· 2025-09-11 13:39
证券日报网讯益盛药业9月11日在互动平台回答投资者提问时表示,截至2025年9月10日,公司股东总户 数20,399户。 (文章来源:证券日报) ...
益盛药业最新股东户数环比下降6.23%
Summary of Key Points Core Viewpoint - Yisheng Pharmaceutical reported a decrease in the number of shareholders and a decline in both revenue and net profit for the first half of the year, indicating potential challenges for the company moving forward [2]. Shareholder Information - As of August 31, the number of shareholders for Yisheng Pharmaceutical was 20,554, a decrease of 1,366 from the previous period (August 20), representing a decline of 6.23% [2]. Stock Performance - The closing price of Yisheng Pharmaceutical was 8.08 yuan, reflecting an increase of 1.38%. However, since the concentration of shares began, the stock price has cumulatively decreased by 6.05%, with 2 days of increase and 6 days of decrease during the reporting period [2]. Financial Performance - For the first half of the year, Yisheng Pharmaceutical achieved a revenue of 328 million yuan, a year-on-year decrease of 5.75%. The net profit was 18.76 million yuan, down 43.71% year-on-year. The basic earnings per share were 0.0567 yuan, and the weighted average return on equity was 0.84% [2].
交个朋友、益盛药业等成立健康管理公司
Group 1 - A new company named Hangzhou Youxuan Youyi Health Management Co., Ltd. has been established, with Cui Dongsheng as the legal representative [1] - The company's business scope includes the acquisition of primary agricultural products, sales of agricultural and sideline products, wholesale of edible agricultural products, and retail of edible agricultural products [1] - The company is jointly held by Jiao Ge Peng You Xuan Technology Co., Ltd. and Yisheng Pharmaceutical (002566) among others [1]
益盛药业2025年中报简析:净利润同比下降43.71%
Zheng Quan Zhi Xing· 2025-08-23 22:27
Financial Performance - Yisheng Pharmaceutical (002566) reported a net profit decline of 43.71% year-on-year for the first half of 2025, with total revenue of 328 million yuan, down 5.75% from the previous year [1] - The gross profit margin decreased to 75.15%, a drop of 2.02% year-on-year, while the net profit margin fell to 6.05%, down 36.94% [1] - The company’s total expenses (selling, administrative, and financial) reached 219 million yuan, accounting for 66.83% of revenue, an increase of 2.16% year-on-year [1] Cash Flow and Financial Ratios - The company experienced a significant increase in financial expenses by 502.37% due to reduced interest income [3] - The net cash flow from investment activities increased by 100.86%, attributed to higher cash recovered from investments compared to the previous year [3] - The company’s return on invested capital (ROIC) was reported at 2.08%, indicating historically weak capital returns [3] Accounts Receivable and Inventory - The accounts receivable to profit ratio reached 312.96%, suggesting potential issues with cash collection [4] - The inventory to revenue ratio stood at 241.32%, indicating a high level of inventory relative to sales [4] Strategic Focus - The company plans to increase its research and development efforts to meet market demands, addressing concerns about the lack of new product development in traditional Chinese medicine [5]
吉林省集安益盛药业股份有限公司2025年半年度报告摘要
Core Points - The company has not distributed cash dividends or bonus shares during the reporting period [3] - The company has implemented a rectification plan to address issues related to shareholding by proxy, ensuring accurate disclosure of shareholder information [5] - The board of directors and supervisory board have both approved the 2025 semi-annual report, confirming its compliance with legal and regulatory requirements [10][12] Company Overview - The company is identified as Jilin Province Jichang Yisheng Pharmaceutical Co., Ltd. with the stock code 002566 [1] - The company has not experienced any changes in its controlling shareholder or actual controller during the reporting period [6][7] Financial Information - The company has not reported any preferred shareholders or related data during the reporting period [8] - The company has not issued any bonds that are still in existence as of the date of the semi-annual report [9]
益盛药业:第九届董事会第二次会议决议公告
Zheng Quan Ri Bao· 2025-08-22 15:48
Core Viewpoint - Yisheng Pharmaceutical announced the approval of its 2025 semi-annual report and summary by the company's ninth board of directors during its second meeting [2] Group 1 - The announcement was made on the evening of August 22 [2] - The report includes financial performance and operational highlights for the first half of 2025 [2]
益盛药业:第九届监事会第二次会议决议公告
Zheng Quan Ri Bao· 2025-08-22 15:46
Core Viewpoint - Yisheng Pharmaceutical announced the approval of its 2025 semi-annual report and summary by the second meeting of the ninth supervisory board [2] Group 1 - The announcement was made on the evening of August 22 [2] - The report includes financial performance and operational updates for the first half of 2025 [2]
益盛药业:截至2025年8月20日公司股东总户数为21920户
Zheng Quan Ri Bao Wang· 2025-08-22 11:46
Core Insights - Yisheng Pharmaceutical (002566) reported that as of August 20, 2025, the total number of shareholders is 21,920 [1] Company Summary - The company has engaged with investors through an interactive platform, providing updates on shareholder statistics [1]